New Training Program for Men Receiving Hormone Therapy for Prostate Cancer
Tests a new exercise program in men with prostate cancer on hormone therapy.
Plain-language title generated from the registry record
Registry title: Training for Men Undergoing Androgen Deprivation Therapy.
Key facts
- Where
- Stockholm, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT06449664, who can take part
Where in Sweden
- Swedish School of Sport and Health SciencesStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Swedish School of Sport and Health Sciences
- Trial code
- NCT06449664
- Record updated
- 10 June 2024
- Original description
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).Read full original descriptionShow less
ADT-Train - A New Training Concept for Men With Prostate Cancer Receiving Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
The main questions it aims to answer are:
* How feasible and safe is the new training concept? * How efficient is the training concept to counteract side effects caused by ADT?
Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects.
Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.
Inclusion: signed informed consent; histologically confirmed localised or locally advanced prostate cancer; planned radiotherapy in combination with ADT for at least six months (unfavorable intermediate risk and high-risk prostate cancer) with curative intent and with no known metastasis.
Exclusion: on-going or previously treated with ADT or other hormonal treatments; very high risk localised prostate cancer planned for radiotherapy and ADT plus abiraterone and cortisone; localized prostate cancer planned for radiotherapy without ADT; have any contraindications to physical testing/exercise as per the ACSM guidelines; unable to comply with study procedures.